Totrophenolone-like new skeleton compound B as well as preparation method and application thereof
Through the new trophene-like skeleton compound B isolated from Mongolian medicine vesicle, the toxicity and drug resistance of existing gastric cancer treatment drugs were solved, and the significant anti-cancer effect on gastric cancer cells was achieved, providing new anti-gastric cancer drugs with a significant anti-gastric cancer drug. The foundation is.
Patent Information
- Application Number
- CN202410925611.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-08
AI Technical Summary
Existing gastric cancer treatment drugs have problems with drug toxicity and drug resistance, and there is a lack of effective natural drugs for early-stage gastric cancer treatment.
A new trophene-like skeleton compound B was isolated from Mongolian Pharmaceutical Cystella and identified by multiple chromatographic separation and spectroscopy techniques. It was ethanol cold leaching, polar site extraction, reverse phase ODS column chromatography separation, and MCI column Chromatography separation and reverse phase preparation Liquid chromatography purification and enrichment methods were prepared for anti-gastric cancer research.
This compound has a significant anti-cancer effect on human gastric cancer cell HGC-27, with an IC50 value of 7.02μM, which can induce cell apoptosis and provide a material basis for the development of new anti-gastric cancer drugs.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of natural drug chemistry, and specifically relates to a new tropolone-like skeleton compound B separated from Mongolian medicine Phyllanthus truncatula and a preparation method thereof, and also relates to the application of the compound in the preparation of anti-gastric cancer drugs. Background Art
[0002] Gastric cancer (GC) is a malignant tumor originating from gastric mucosal epithelial cells. There are more than 1 million new cases worldwide each year, making it the third most common cause of cancer-related deaths worldwide. According to statistics, due to changes in dietary structure, emotional anxiety caused by work pressure, and Helicobacter pylori infection, the number of new gastric cancer patients in my country tends to be younger. The technical means of treating gastric cancer in the clinic mainly include surgical resection, chemotherapy, radiotherapy, etc. Most gastric cancer patients are already in the middle and late stages when they are diagnosed because of their early symptoms. They miss the best time for surgical treatment and can only take drug chemotherapy. At present, the first-line clinical drugs that can improve the survival rate of gastric cancer patients worldwide include oxaliplatin, irinotecan, fluorouracil, etc., but all of them have problems of drug toxicity and drug resistance. Unlike chemical drugs, natural drugs have the characteristics of natural non-toxicity, immune regulation, and multiple targets, and they play an increasingly important role in the treatment of gastric cancer. Therefore, finding and developing new targets from natural products with high efficacy and low toxicity of chemotherapy drugs is one of the research and development directions for the clinical treatment of gastric precancerous lesions and gastric cancer.
[0003] Physochlaina physaloides (L.) G.Don is a dried rhizome of the Solanaceae plant Physochlaina physaloides (L.) G.Don. It was first recorded as a Mongolian medicine in the Mongolian classic book "Infallible Mongolian Medicine Mirror". Its Mongolian name is "Hun-Haorisu" or "Tangpurumu". It is mainly produced in Inner Mongolia, Heilongjiang, Hebei and other places. The rhizome of Physochlaina physaloides has a strong aromatic smell and an appearance that is very similar to ginseng. Its ethanol tincture is often used in Mongolian medicine to treat gastrointestinal inflammation, spasms, brain tingling, tumors and microbial infections. Current studies have found that Physochlaina mainly contains dihydroflavonoids, flavonol glycosides, hydroxycoumarins, tropane alkaloids and other ingredients, but the structure and activity are known, and there is a lack of in-depth systematic chemical research. In particular, the active ingredients in Physochlaina that have toxic effects on gastric cancer are still unclear.
[0004] In order to further discover compounds with novel structures and good anti-tumor activity, the present invention adopts a variety of chromatographic separation methods, such as ODS, MCI column chromatography and preparative HPLC, and uses a variety of spectral techniques, such as nuclear magnetic resonance, high-resolution mass spectrometry, electron circular dichroism, etc., to discover a new tropolone-like skeleton compound B from the n-butanol part of the Mongolian medicine vesicle grass ethanol extract, and includes its preparation method and application in anti-gastric cancer. Summary of the invention
[0005] The present invention conducts systematic research on the chemical composition and biological activity of Phragmites australis, and isolates a new tropolone-like skeleton compound B therefrom, and the compound exhibits excellent anti-gastric cancer activity.
[0006] The structural formula of the new tropolone-like skeleton compound provided by the present invention is shown in Formula I:
[0007]
[0008] The compound was identified as 2-isopropenyl-4-methyl-6-[3,4,5-trihydroxy-6-
[0009] (3,4,5-trihydroxy
[0010] -6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-tetrahydro-pyran-2-yloxy]-2,3-dihydro-1H-azulen-5-oen, formula C 26 H 36 O 12 , named Physochlosides B.
[0011] The preparation process of the new tropolone-like skeleton compound shown in Formula I provided by the present invention is as follows:
[0012] (1) Ethanol cold extraction: The dried roots of Physostomum villosum were mechanically crushed at room temperature, soaked in ethanol and extracted with ultrasound assistance, and the extract was collected and concentrated under reduced pressure to obtain the total ethanol extract;
[0013] (2) Extraction of polar parts: dissolving 0.34 kg of total ethanol extract per 1 L of water and suspending the total ethanol extract in water to obtain a suspension, extracting the suspension with petroleum ether, ethyl acetate, and n-butanol in a volume ratio of 1:3:3:3, collecting the n-butanol extract and concentrating it under reduced pressure to obtain n-butanol extract;
[0014] (3) Reverse-phase ODS column chromatography separation: a small amount of methanol was dissolved in the n-butanol fraction, and the fraction was chromatographed on a reverse-phase ODS column, with a gradient elution of methanol-water (20:80 to 80:20, v / v). After TLC analysis, the same fractions were combined to obtain 7 main fractions (Fr.A to Fr.G);
[0015] (4) Reverse phase MCI column chromatography separation: The dried main fraction Fr.C containing the compound of formula I was dissolved in methanol-water solution, and subjected to MCI column chromatography, with gradient elution using methanol-water (20:80-70:30, v / v). After TLC analysis, the same fractions were combined to obtain 5 secondary fractions (Fr.C1-Fr.C5);
[0016] (5) Reverse phase ODS column chromatography separation: The dried secondary fraction Fr.C1 containing the compound of formula I was dissolved in methanol-water solution, and subjected to ODS column chromatography, with gradient elution using methanol-water (20:80-85:15, v / v). After TLC analysis, the same fractions were combined to obtain five main fractions (Fr.C1.1-Fr.C1.5);
[0017] (6) Reverse phase preparative liquid chromatography purification and enrichment: The dried secondary fraction Fr.C1.5 containing the compound of formula I is dissolved in methanol-water solution and separated by reverse phase preparative liquid chromatography (C18) to obtain the compound of formula I at a retention time of 25.0 to 30.0 min.
[0018] The present invention also provides preliminary testing and evaluation of Physochlosides B in terms of anti-gastric cancer activity in vitro, and the selected tumor cell line is human gastric cancer cell line (HGC-27).
[0019] The results showed that the new tropolone skeleton compound provided by the present invention has a significant anti-gastric cancer effect, and the IC 50 The value is 7.02 μM, and it can significantly induce apoptosis of HGC-27 cells. Therefore, the compound provided by the present invention can be used in the development of anti-gastric cancer drugs.
[0020] The beneficial effects of the present invention are:
[0021] The present invention extracts and separates a new tropolone skeleton compound B shown in formula I from the rhizomes of the Mongolian medicine Vesicle grass. Activity evaluation experiments show that the compound has significant anti-gastric cancer activity and can be further prepared for more in-depth pharmacological research. The present invention provides a material basis for new anti-gastric cancer drugs and is conducive to the further development of the medicinal value and clinical application of the Mongolian medicine Vesicle grass. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The NMR of the compounds of the present invention is 1 H-NMR spectrum;
[0023] Figure 2 The NMR of the compounds of the present invention is 13 C-NMR spectrum;
[0024] Figure 3The two-dimensional nuclear magnetic resonance of the compound of the present invention 1 H- 1 H COSY spectrum;
[0025] Figure 4 is a two-dimensional nuclear magnetic resonance HSQC spectrum of the compound of the present invention;
[0026] Figure 5 is a two-dimensional nuclear magnetic resonance HMBC spectrum of the compound of the present invention;
[0027] Figure 6 The main compounds of the present invention are 1 H- 1 Correlation diagram of H COSY and HMBC signals;
[0028] Figure 7 CD and ECD calculated spectra of the compounds of the present invention;
[0029] Figure 8 is a high-resolution mass spectrum of the compound of the present invention;
[0030] Fig. 9 The toxic effect of the compound of the present invention on gastric cancer HGC-27 cells;
[0031] Fig.10 The effect of the compound of the present invention on apoptosis of gastric cancer HGC-27 cells; DETAILED DESCRIPTION
[0032] The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments. The experimental methods in the following examples are conventional methods unless otherwise specified; the materials, reagents, etc. used in the following examples are all available from public commercial channels unless otherwise specified.
[0033] Example 1: Preparation method of Physochlosides B
[0034] ① Acquisition of raw materials: The rhizomes of Physochlaina physaloides (L.) G.Don were collected from Xinghe County, Ulanqab League, Inner Mongolia Autonomous Region in August 2019. The specimens are currently stored in the Herbarium of Inner Mongolia University (No. HIMC0031223). The collected fresh rhizomes were dried in a constant temperature electric oven at 45°C to constant weight.
[0035] ② Extract extraction: Take 5.0 kg of dried roots of Sophora flavescens, grind them mechanically, soak them in 95% ethanol for 24 hours, and then perform ultrasonic-assisted extraction for 3 hours (solid-liquid ratio = 1:3). Repeat the extraction procedure for 3 days, combine the extracts, and concentrate under reduced pressure at 40-45°C to obtain 0.68 kg of total ethanol extract.
[0036] ③ Extraction of extract: 0.68 kg of total ethanol extract was suspended in 2 L of ultrapure water, extracted with petroleum ether (6 L), ethyl acetate (6 L), and n-butanol (6 L) in sequence, and the extract was concentrated under reduced pressure at 40-45 ° C to obtain 13 g of petroleum ether fraction, 28 g of ethyl acetate fraction, and 39 g of n-butanol fraction.
[0037] ④ Reverse phase ODS column chromatography separation: Take 39g of the above n-butanol fraction and dissolve it with a small amount of methanol for later use. Load the column with ODS filler (particle size 75μM), wet sample loading, gradient elution with methanol-water (20:80-80:20, v / v), TLC thin layer chromatography tracking analysis, and combine the same fractions to obtain 7 main fractions (Fr.A-Fr.G).
[0038] ⑤ Reverse phase MCI column chromatography separation: Take 6.2g of the dried main fraction Fr.C (50% methanol water elution component), dissolve it with methanol and water (1:4, v / v). Load the column with MCI filler (particle size 75μM), wet sample loading, gradient elution with methanol-water (20:80~70:30, v / v), TLC thin layer chromatography tracking analysis, and combine the same fractions to obtain 5 secondary fractions (Fr.C1~Fr.C5).
[0039] ⑥ Reverse phase ODS column chromatography separation: Take 2.5g of the dried secondary fraction Fr.C1 (60% methanol water elution component) and dissolve it with methanol and water (1:4, v / v). Load the column with ODS filler (particle size 50μM), wet sample loading, gradient elution with methanol-water (20:80-85:15, v / v), TLC thin layer chromatography tracking analysis, and combine the same fractions to obtain 5 secondary fractions (Fr.C1.1-Fr.C1.5).
[0040] ⑦ Purification and enrichment by reversed-phase preparative liquid chromatography; take 1.1 g of the dried secondary fraction Fr C1.5 (60% methanol water elution component), dissolve and filter it with methanol and water (2:3, v / v), and repeat the purification and enrichment by reversed-phase preparative liquid chromatography (C-18) at a flow rate of 8 mL / min, dual-channel wavelengths of 254 nm and 280 nm, and a mobile phase of methanol: water (40:60-80:20, v / v). The compound was obtained at a retention time of about 28.4 min.
[0041] Example 2: Structural identification of Physochlosides B
[0042] Colorless amorphous solid, Q-TOF-MS results show m / z: 539.2207 [M-H] - , indicating that its molecular weight is 540. 1 H and 13 C (Table 1) determines its molecular formula to be C 26 H 36 O12 , the calculated unsaturation is 9.
[0043] Table 1. Compounds of Formula I in DMSO-d6 1 H-NMR (500 MHz) and 13 C-NMR (500 MHz) chemical shift data
[0044]
[0045]
[0046] Refer to the attached Figures 1 to 8 , combined with the data in Table 1. There are two sugar groups in the compound molecule, and the hydrogen signals on the terminal carbon are [δ H 4.79 (d, J = 7.8 Hz)] and [δ H 4.21 (d, J = 7.8 Hz)], and since the coupling constants were all 7.8 Hz, it was determined to be a β configuration. In addition to the above sugar groups, there are two methyl groups [δ Me-13 1.76 (br s); δ Me-14 2.20 (br s)], three methylene groups [δ H-1a 2.89(m),δ H-1b 3.05(m);δ H-3a 2.87(m),δ H-3b 3.14(m);δ H-12a 4.77(br s),δ H-12b 4.80 (br s)], three methine groups [δ H-2 2.87(m);δ H-7 7.19 (d, J = 9.8 Hz); δ H-8 7.00 (br d, J = 9.8 Hz)], a carbonyl carbon (δ C-5 178.5) and six olefin carbon signals. Further analysis of the two-dimensional NMR spectrum revealed that 1 H- 1The presence of a five-membered ring and an isopropenyl group on the right side of the backbone was confirmed by three spin systems H(1)-H(2)-H(3), H(7)-H(8), and H(11)-H(12)-H(13) in H COSY, and three correlations of H3-13 with C-2, C-11, and C-12; H-12 with C-2, C-11; and H-1 with C-2, C-3, C-8, C-9, and C-11 in HMBC. Another spin system H(7)-H(8), and three correlations of H3-14 with C-4, C-5, and C-10; H-7 with C-5, C-6, and C-9; and H-8 with C-6, C-7, and C-10 confirmed the presence of a seven-membered ring on the left side of the backbone. The attachment position of the sugar group was determined by HMBC correlations of H-1' to C-6' and H-1" to C-6". In addition, according to the results of the hydrolysis reaction, it was determined that the sugar groups in the compound were all D-glucose. The absolute configuration of the compound was determined by ECD calculation, and the results showed that the 2-S configuration was consistent with the actual CD spectrum of the compound. Based on the above evidence, the structure of the compound was determined to be 2-isopropenyl-4-methyl-6-[3,4,5-trihydroxy-6-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-tetrahydro-pyran-2-yloxy]-2,3-dihydro-1H-azulen-5-oen, referred to as Physochlosides B.
[0047] Example 3: Anti-gastric cancer effect of Physochlosides B
[0048] The in vitro antitumor activity of the new tropolone-like skeleton compound represented by Formula I was investigated. The tumor cell line used in the relevant experiments was gastric cancer HGC-27 cells. The results are shown in the attached Figures 9-10 .
[0049] ① Cytotoxicity: After diluting the HGC-27 cells in logarithmic phase into a cell suspension with culture medium, inoculate them into a sterile cell plate (96-well), with a volume of 80 μL per well and a density of 5000 cells per well. After the inoculated cell plate was placed in a CO2 incubator overnight, 10 μL of the test compound (5, 10, 25, 50 μM) was added to each well of the treatment group, and the same volume of physiological saline was added to each well of the control group. After incubation in the CO2 incubator for 48 hours, 20 μL of thiazolyl blue (MTT) solution was added to each well and cultured for 4 hours. The culture medium was discarded, and 150 μL of DMSO was added. The mixture was shaken evenly to make the formazan in the living cells The crystals were fully dissolved. The absorbance of each well of the cell plate was measured by an ELISA reader at 570 nm, and the results were repeated three times independently.
[0050] IC calculated by linear regression 50 The results showed that the compounds of the present invention had significant toxic effects on human gastric cancer HGC-27 cells, IC 50 ② Cell apoptosis: HGC-27 cells in logarithmic phase were diluted with culture medium to form a cell suspension, which was inoculated into a sterile cell plate (24 wells) with a volume of 200 μL per well and a density of 2×10 4 Cells per well. After the inoculated cell plate was placed in a CO2 incubator overnight, different concentrations (0, 10, 25, 50 μM) of the test compound were added to each well of the treatment group. After continuing to culture for 48 hours, the cell plate was removed, washed once with PBS, and 1 mL of 4% paraformaldehyde was added to fix the cells. After standing at room temperature for 15 minutes, the cells were washed once with PBS, and an appropriate amount of 5 μg / mL Hoechst 33342 dye solution was added to cover the cells, and incubated at 37°C for 10 minutes. After sufficient staining, the dye solution was aspirated, and the cells were washed 3 times with PBS for 3 minutes each time, and directly observed and photographed under a fluorescence microscope.
[0051] Hoechst 33342 fluorescent dye can pass through normal cell membranes in small amounts, causing normal cells to be stained with uniform low-brightness blue fluorescence. Apoptotic cells, due to the damaged function of P-glycoprotein on the cell membrane, have enhanced membrane permeability, allowing the fluorescent dye to enter in large quantities, thereby presenting dense high-brightness blue fluorescence. As a result, HGC-27 cells treated with the compound of the present invention showed dense high-brightness blue fluorescence. As the treatment concentration increased, the number of apoptotic cancer cells in the field of view also increased significantly.
[0052] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which are all covered by the protection scope of the present invention.
Claims
1. A new tropolone-like skeleton compound B, characterized in that: The structural formula of the new tropolone skeleton compound B is shown in Formula I: The novel tropolone-like skeleton compound B was identified as 2-isopropenyl-4-methyl-6-[3,4,5-trihydroxy-6-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-tetrahydro-pyran-2-yloxy]-2,3-dihydro-1H-azulen-5-oen, with a molecular formula of C 26 H 36 O 12 , named Physochlosides B, there are two sugar groups in the compound molecule, and the hydrogen signals on the terminal carbon are [δ H 4.79 (d, J = 7.8 Hz)] and [δ H 4.21(d,J=7.8Hz)], and the coupling constants are all 7.8Hz.
2. A tropolone-like new skeleton compound B as claimed in claim 1, characterized in that: The preparation method of the new tropolone skeleton compound B comprises the following steps: (1) Ethanol cold extraction: The dried roots of Physostomum villosum were mechanically crushed at room temperature, soaked in ethanol and extracted with ultrasound assistance, and the extract was collected and concentrated under reduced pressure to obtain the total ethanol extract; (2) Extraction of polar parts: dissolving 0.34 kg of total ethanol extract per 1 L of water and suspending the total ethanol extract in water to obtain a suspension, extracting the suspension with petroleum ether, ethyl acetate, and n-butanol in a volume ratio of 1:3:3:3, collecting the n-butanol extract and concentrating it under reduced pressure to obtain n-butanol extract; (3) Reverse-phase ODS column chromatography separation: a small amount of methanol was dissolved in the n-butanol fraction, and the fraction was chromatographed on a reverse-phase ODS column, eluted with a methanol-water gradient, and after TLC analysis, the same fractions were combined to obtain 7 main fractions; (4) Reverse phase MCI column chromatography separation: the main fraction Fr.C was taken, dissolved in methanol-water solution, subjected to MCI chromatography column chromatography, and eluted with methanol-water gradient. After thin layer TLC analysis, the same fractions were combined to obtain 5 secondary fractions; (5) Reverse phase ODS column chromatography separation: The dried secondary fraction Fr.C1 containing the compound of formula I was dissolved in methanol-water solution, subjected to ODS column chromatography, and subjected to methanol-water gradient elution. After thin layer TLC analysis, the same fractions were combined to obtain 5 main fractions; (6) Reverse phase preparative liquid chromatography purification and enrichment: The dried secondary fraction Fr.C1.5 containing the compound of formula I is dissolved in methanol-water solution and separated by reverse phase preparative liquid chromatography to obtain the compound of formula I at a retention time of 25.0 to 30.0 min.
3. Use of the novel tropolone skeleton compound as claimed in claim 1 for inducing apoptosis in HGC-27 cells.
